Management of atrial fibrillation in people with haemophilia - A consensus view by the ADVANCE Working Group

Haemophilia

Volumn 20, Issue 6, 2014, Pages e417-e420

  Schutgens, Roger E G ^a   Klamroth, R ^b   Pabinger, I ^c   Dolan, G ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9;

ABLATION THERAPY; AGE; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE ABLATION; BLEEDING; BLOOD SUBSTITUTION; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIRECT CURRENT CARDIOVERSION; DISEASE PREDISPOSITION; EUROPE; EVIDENCE BASED PRACTICE; HEMOPHILIA; HUMAN; LETTER; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT INDICATION; COMPLICATION; DISEASE MANAGEMENT; HEMOPHILIA A; HEMOPHILIA B; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DISEASE MANAGEMENT; HEMOPHILIA A; HEMOPHILIA B; HUMANS; PRACTICE GUIDELINES AS TOPIC; STROKE;

EID: 84931957095     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12525     Document Type: Letter

References (10)

1. Darby SC, Kan SW, Spooner RJ et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25.
2. Mauser-Bunschoten EP, Fransen van de Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-63.
3. Kulkarni R, Soucie JM, Evatt BL. Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol 2005; 79: 36-42.
4. Fransen van de Putte DE, Fischer K, Makris M et al. History of non-fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia. Eur J Haematol 2012; 89: 336-9.
5. Schutgens RE, Klamroth R, Pabinger I, Malerba M, Dolan G. Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe. Haemophilia 2014; epub ahead of print.
6. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.
7. Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat agerelated morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256-63.
8. Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a Delphi group opinion technic. N Engl J Med 1973; 288: 1272-5.
9. Camm AJ, Lip GY, De CR et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
10. Cheung VT, Hunter RJ, Ginks MR, Schilling RJ, Earley MJ, Bowles L. Management of thromboembolic risk in persons with haemophilia and atrial fibrillation: is left atrial appendage occlusion the answer for those at high risk? Haemophilia 2013; 19: e84-6.